Articles

Advance care planning is the process of planning for future medical treatment in the event that patients are unable to make their own decisions. It ensures that patients receive healthcare services that are consistent with their personal wishes, culture, goals, and values. Read More ›

Breast cancer cryoablation, which destroys tumor cells by exposing them to subfreezing temperatures, appears to be an effective alternative to surgery for women aged >60 years with low-risk, early-stage breast cancer, according to findings from the ICE3 trial. Read More ›

The recent approval of several new targeted therapies has led to significant advances in the treatment of patients with HER2-positive metastatic breast cancer. Read More ›

According to the American Cancer Society, nearly 35,000 new cases of multiple myeloma will be diagnosed in the United States in 2021, and approximately 12,410 deaths will be attributed to the disease. Read More ›

The COVID-19 pandemic may have temporarily overshadowed the opioid crisis in the United States, but deaths related to opioid overdose have risen to an all-time high in the past year. Read More ›

Treatment with tebentafusp (IMCgp100), a novel bispecific T-cell receptor (TCR) fusion protein, extended survival in patients with metastatic uveal melanoma, according to the results from a recent phase 3 trial. Read More ›

Hot flashes, fatigue, back and joint pain, and anxiety are some of the symptoms and concerns frequently reported by early-stage breast cancer survivors, according to results from a study of 98 women with low-risk stage I/II estrogen/progesterone-positive, HER2/neu-negative cancers. Read More ›


Although standard chemotherapy is often effective in the first-line treatment of locally invasive urothelial carcinoma, until recently, there have been few second- or third-line treatment options for patients with advanced or metastatic disease. Read More ›

Lung cancer remains the leading cause of cancer death worldwide, but the treatment landscape is rapidly evolving. In the past 10 years alone, the number of drugs approved by the FDA for non–small-cell lung cancer (NSCLC) has exceeded the previous 10 decades combined. Read More ›

Page 78 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: